Lebanese Pharma Watches the Sun-Organon Deal

Lebanese distributors of Organon women's health brands are reportedly reviewing their exposure following the announced takeover of the US drugmaker by India's Sun Pharma , according to a Reuters report carried by Asharq Business on April 26, 2026. Supply continuity for the affected products has not been confirmed. The transaction is valued at $11.75 billion. Organon was spun off from Merck & Co. in 2021 and is best known for its portfolio of women's health products, biosimilars, and established off-patent brands. What Local Distributors Are Watching Locally, the reported review centers on Organon's women's health line, which is carried in the Lebanese market by pharmaceutical agents. Distributors are reportedly looking at contract terms, inventory cover, and the timing of any portfolio decisions Sun Pharma may take after the deal closes. Lebanon's pharmaceutical sector has been operating under tight foreign currency constraints since 2019, and any disruption to imports of essential medicines tends to draw immediate attention from local agents and regulators. No public statement on the deal has been issued by a Lebanese regulatory or industry body as of publication. How the Sun Pharma Deal Sits Globally If completed, the acquisition would expand Sun Pharma's reach in women's health and biosimilars, two segments where Organon has built a global footprint. The deal still requires regulatory approvals in multiple jurisdictions before it can close, and the combined company's product strategy has not been detailed publicly. For Lebanese importers, the practical questions are narrow. Which Organon products will continue to be supplied through existing channels, and on what terms. Those answers are not yet on the table.